Abstract
In children with steroid-resistant nephrotic syndrome (SRNS) hyperlipidaemia may in the long term be associated with progressive renal insufficiency and increased risk of coronary heart disease. We have assessed the efficacy and tolerability of diet prior to and in combination with a hydroxymethylglutaryl CoA reductase inhibitor, simvastatin, in seven children with SRNS with a mean age of 8 years (range 1.8–16.3 years). Dietary advice to maintain adequate energy and protein intakes with reduced saturated fat and cholesterol intake had little impact on lipid levels pre treatment (mean reduction in cholesterol 1 mmol/l, triglyceride 1.1 mmol/l) but was maintained throughout the study duration. The mean cholesterol and triglyceride concentrations pre treatment were 12.1±2 (SEM) mmol/l and 8±2.1 (SEM) mmol/l, respectively. On a median simvastatin dose of 10 mg/day (range 5–40 mg) there was a 41% reduction in cholesterol to 6.6±0.77 (SEM) mmol/l and a 44% reduction in triglyceride to 3.9±1.38 (SEM) mmol/l at 6 months which was sustained at 12 months in five patients. The drug was well tolerated with no clinical side effects being noted. Over 6 months the mean plasma albumin concentrations increased from 18.2±1.26 (SEM) g/l to 23±2.51 (SEM) g/l, accounted for by three patients (1 complete remission, 1 partial remission, 1 end-stage renal failure). Plasma creatinine concentrations remained stable in five patients with two having progressive chronic renal failure. Growth parameters for both weight and height were maintained. Simvastatin has a beeficial effect on abnormal lipid levels in SRNS but the effectiveness of long-term therapy needs to be evaluated.
Similar content being viewed by others
References
Warwick GL, Packard CJ (1993) Lipoprotein metabolism in the nephrotic syndrome. Nephrol Dial Transplant 8:385–396
Watson AR, Coleman JE (1993) Dietary management in nephrotic syndrome. Arch Dis Child 69:2:179–180
Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome (1994) Arch Dis Child 70:151–157
Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet II:1309–1312
Kees-Folts D, Diamond JR (1993) Relationship between hyperlipidaemia, lipid mediators and progressive glomerulosclerosis in the nephrotic syndrome. Am J Nephrol 13:365–375
Ducobu J, Brasseur D, Chaudron J-M, Deslypere J-P, Harvengt C, Muls E, Thomson M (1992) Simvastatin use in children. Lancet 339:1488
Sinzinger H, Schmid P, Pirich CH, Virgolini I, Pesau B, Granegger S, O'Grady J (1992) Treatment of hypercholesterolaemia in children. Lancer 340:548–549
Coleman JE (1994) The kidney. In: Shaw V, Lawson M (eds) Clinical paediatric dietetics. Blackwell, Oxford, pp 130–131
Department of Health (1991) Dietary reference values for food energy and nutrients. HMSO, London, UK
Holland B, Welch AA, Unwin ID, Buss DH, Paul AA, Southgate DAT (1991) McCance and Widdowson's The composition of foods, 5th edn. RSC/MAFF, Cambridge, UK
Thomas ME, Harris KPG, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, Williams JD, Walls J, Moorhead JF (1993) Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 44: 1124–1129
Department of Health (1994) Nutritional aspects of cardiovascular disease. HMSO, London, UK
Rabelink AJ, Erkelens DW, Hené RJ, Joles JA (1988) Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipaedemia of nephrotic syndrome. Lancet II:1335
Wanner C, Böhler J, Eckardt HG, Weiland H, Schollmeyer P (1994) Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome. Clin Nephrol 41:138–143
Mallick NP, Short CD (1981) The nephrotic syndrome and ischaemic heart disease. Nephron 27:54–57
Wass V, Cameron JS (1981) Cardiovascular disease and the nephrotic syndrome: the other side of the coin. Nephron 27:58–61
MASS investigators (1994) Effect of simvastatin on coronary atheroma: the multicentre Anti-Atheroma Study (MASS). Lancet 344:633–638
Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coleman, J.E., Watson, A.R. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 10, 171–174 (1996). https://doi.org/10.1007/BF00862065
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00862065